Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis
Capsule Summary: Spironolactone has a good long-term safety profile and has not been shown to increase the risk of developing cancer. Spironolactone may be a viable treatment option for alopecia in women who are under breast cancer remission and is not associated with an increased risk for breast cancer recurrence.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Chapman Wei, Patawut Bovonratwet, Alex Gu, Gaby Moawad, Peter K. Sculco, Jonathan I. Silverberg, Adam J. Friedman Source Type: research
More News: Academies | Alopecia | Breast Cancer | Cancer | Cancer & Oncology | Dermatology | Skin | Spironolactone | Women